// App-Quantinova.ai

: Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).

Researchers

Presenter

  • Archana Agarwal

Principal Investigators

  • Amin Nassar

  • Gregory Russell Pond

  • Justine A. Barletta

  • Andres Acosta

  • Sarah Abou Alaiwi

  • Catherine Curran

  • Guru Sonpavde

Medical Centers

  • Dana-Farber Cancer Institute at St. Elizabeths Medical Center, Brighton, MA

  • Brigham and Women's Hospital, Brookline, MA

  • McMaster University, Hamilton, ON, Canada

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved